Scalper1 News
Shares of several drugmakers soared Monday after a study published over the weekend said that their next-generation cholesterol drugs could cut the risk of heart disease, which is the world’s No. 1 killer. Highly rated Regeneron (REGN) broke out, and closed Monday’s session still in buy range. Its drug development partner Sanofi (SNY) rose on the news too. So did Amgen (AMGN), whose own heart disease treatment also showed positive results. Watch Scalper1 News
Scalper1 News